Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of HSK39297 versus eculizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
CTR20250251Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ciprocopan, eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Jan 2025; status: completed.
02
Drugs
ciprocopaneculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20250251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250251.